|
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
|
mathematical ability
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals.
|
30038396 |
2018 |
|
Smoking
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Mercapturic Acids Derived from the Toxicants Acrolein and Crotonaldehyde in the Urine of Cigarette Smokers from Five Ethnic Groups with Differing Risks for Lung Cancer.
|
26053186 |
2015 |
|
Smoking Behaviors
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Mercapturic Acids Derived from the Toxicants Acrolein and Crotonaldehyde in the Urine of Cigarette Smokers from Five Ethnic Groups with Differing Risks for Lung Cancer.
|
26053186 |
2015 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
GWASCAT |
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.
|
23128233 |
2012 |
|
Inflammatory Bowel Diseases
|
0.100 |
GeneticVariation
|
group |
GWASDB |
Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease.
|
23128233 |
2012 |
|
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Leupaxin stimulates adhesion and migration of prostate cancer cells through modulation of the phosphorylation status of the actin-binding protein caldesmon.
|
26079947 |
2015 |
|
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Leupaxin acts as a mediator in prostate carcinoma progression through deregulation of p120catenin expression.
|
19701244 |
2009 |
|
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells.
|
17329398 |
2007 |
|
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Following downregulation of LPXN expression by L2-siRNA, proliferation inhibition rates increased to 27.043±2.051 and cell transmembrane invasion rates decreased to 25.270±2.145 (P<0.05).
|
30655748 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Several studies have reported that LPXN regulates cancer development; however, the role of LPXN in bladder cancer remains unknown.
|
29975926 |
2018 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These results provide a novel insight into the role of LPXN in tumorigenesis and progression of bladder cancer and potential therapeutic target of bladder cancer.
|
29975926 |
2018 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Several studies have reported that LPXN regulates cancer development; however, the role of LPXN in bladder cancer remains unknown.
|
29975926 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
ETV6-LPXN fusion transcript generated by t(11;12)(q12.1;p13) in a patient with relapsing acute myeloid leukemia with NUP98-HOXA9.
|
26542893 |
2016 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
In the present study we were able to show by using a cDNA cancer profiling array that leupaxin is upregulated in breast and endometrial cancer, whereas downregulation of leupaxin was observed in lung cancer.
|
25955236 |
2015 |
|
Malignant neoplasm of prostate
|
0.020 |
PosttranslationalModification
|
disease |
BEFREE |
Subsequent analyses of the downstream kinases revealed the extracellular signal-regulated kinase (ERK) as an interaction partner of LPXN that facilitates CaD phosphorylation during LPXN-mediated PCa cell migration.
|
26079947 |
2015 |
|
Tumor Cell Invasion
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Collectively, these results show that leupaxin has particular influence on the progression and invasion of breast cancer cells and may therefore represent an interesting candidate protein for diagnosis and therapeutic interventions.
|
25955236 |
2015 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
In the present study we were able to show by using a cDNA cancer profiling array that leupaxin is upregulated in breast and endometrial cancer, whereas downregulation of leupaxin was observed in lung cancer.
|
25955236 |
2015 |
|
Leukemia, Myelocytic, Acute
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our data indicated that the RUNX1/LPXN and LPXN/RUNX1 fusion proteins may play important roles in leukemogenesis and that deregulation of cell adhesion pathways may be pathogenetically important in AML.
|
19760607 |
2009 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Our study also suggests that LPXN may play an important role in carcinogenesis.
|
19760607 |
2009 |
|
Malignant neoplasm of prostate
|
0.020 |
Biomarker
|
disease |
BEFREE |
Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells.
|
17329398 |
2007 |
|
Pituitary-dependent Cushing's disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
GlycA (glycosylated acute-phase proteins), triglyceride-rich particles (TRLP medium and very small sizes), low-density lipoprotein (LDL) particles (LDLP total and large size), high-density lipoprotein (HDL) particles (HDLP total, medium and small sizes), total cholesterol, LDL-cholesterol, HDL-cholesterol, GlycA inflammatory biomarker, and apolipoprotein B and apolipoprotein A1 (ApoA1) concentrations showed statistically significant changes after remission of CD (p < 0.05).
|
31112990 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High LPXN expression was correlated with large tumor size, advanced tumor stage, and poor survival in bladder cancer patients.
|
29975926 |
2018 |
|
Bladder Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High LPXN expression was correlated with large tumor size, advanced tumor stage, and poor survival in bladder cancer patients.
|
29975926 |
2018 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
High LPXN expression was correlated with large tumor size, advanced tumor stage, and poor survival in bladder cancer patients.
|
29975926 |
2018 |